US Corporate Distress Financial Stress SEC Filings — October 14, 2026

Stock closed below $1.00 for 30 consecutive business days (Aug 26 to Oct 8, 2026), triggering Rule 5450(a)(1) non-compliance with 180 days to cure (deadline April 7, 2027)

Second, separate Nasdaq deficiency (market value of listed securities, notice July 22, 2026) carries a January 19, 2027 deadline that the new bid-price notice does not extend, so cure obligations are stacking

Option to transfer to Nasdaq Capital Market could yield a second 180-day period, a potential reprieve if the company meets initial listing standards excluding bid price

Regained $1.00 minimum bid price compliance after 10 consecutive business days at or above $1.00 (Sept 23 to Oct 6, 2026), confirmed by Nasdaq letter of Oct 7, 2026

Remains non-compliant with Rule 5250(c)(1) for late FY2026 10-K and Q1 FY2027 10-Q, and the Oct 7 letter does not resolve this item

Prior FY2022 through FY2025 financial statements declared unreliable; re-audit of FY2022 through FY2026 by new auditor Adeptus Partners, LLC will reset the reliability of reported results

Auditor Fruci & Associates II resigned effective Aug 12, 2026, following an Item 4.02 non-reliance disclosure, a classic governance red flag

Two concurrent Nasdaq deficiencies (bid price, filed Oct 9, 2026, and market value of listed securities, filed July 22, 2026) with January 19, 2027 and April 7, 2027 deadlines; failure to cure could lead to suspension and delisting

Trading below $1.00 for 30+ days on Nasdaq signals weak market confidence and may constrain access to equity financing, though no enriched financial ratios were available to size balance-sheet stress

Late FY2026 Form 10-K (FYE April 30, 2026) and Q1 FY2027 Form 10-Q (quarter ended July 31, 2026) remain unfiled, with Nasdaq compliance plan due by October 23, 2026 and no assurance of acceptance

Financial statements for FY2022 through FY2025 declared unreliable, implying historical revenue, earnings, and balance-sheet figures may be materially restated

Auditor resignation followed by engagement of a new firm to re-audit five fiscal years increases execution risk, cost, and timing uncertainty for the filing backlog

Bid-price compliance cured on Oct 7, but the open Rule 5250(c)(1) deficiency alone can lead to delisting proceedings if the plan is rejected

Transfer to Nasdaq Capital Market may secure a second 180-day cure period, which could be a positive catalyst if the company meets the market value and other initial listing standards

Sub-$1.00 price after 30 days may create a deep-value entry point for investors with high conviction in a fundamental turnaround, contingent on the company's plan to regain compliance before April 7, 2027

Regained compliance with the $1.00 bid price rule; sustained trading above $1.00 would demonstrate that the price-based deficiency has been resolved, leaving only the filing and governance issues

Successful submission of the Oct 23 compliance plan and timely filing of the FY2026 10-K and Q1 FY2027 10-Q would clear the Rule 5250(c)(1) deficiency and could trigger a re-rating

A completed FY2022 through FY2026 re-audit by Adeptus Partners could provide a clean, verified baseline, which may reduce information uncertainty for patient investors willing to wait for filings

Both filings involve sub-$1.00 trading or market-value deficiencies, showing that listing-standard breaches are an early-warning indicator that often precedes delisting or restructuring for small caps

Netcapital's late filings, non-reliance disclosure, and auditor resignation illustrate how reporting failures compound distress, typically resulting in extended suspension and significant investor dislocation

The 180-day cure periods (AMASS through April 7, 2027; Netcapital's Oct 23 plan deadline) create defined, time-bounded catalysts that investors in distressed listings can use to structure positions

Watch for the Rule 5250(c)(1) compliance plan due to Nasdaq by October 23, 2026, and Nasdaq's decision on acceptance; rejection would raise near-term delisting risk [Oct 23, 2026]

Monitor whether the FY2026 Form 10-K and Q1 FY2027 Form 10-Q are filed, and whether the re-audit by Adeptus Partners progresses to a timetable [date not specified]

Track whether NCPLW holds at or above $1.00 following the Oct 7, 2026 regained-compliance letter, since a relapse would reopen the bid-price deficiency [ongoing]

Monitor progress on the market value of listed securities deficiency with the January 19, 2027 compliance deadline, which the Oct 9 bid-price notice does not affect [Jan 19, 2027]

Track whether AMASS regains $1.00 compliance or transfers to the Nasdaq Capital Market before the April 7, 2027 deadline [Apr 7, 2027]

Watch for an 8-K announcing a transfer request to the Nasdaq Capital Market and notice of intent to cure, which would signal management's strategy [date not specified]